A PYMNTS Company

UK: Roche-Spark deal probed

By  |  September 25, 2019

On Wednesday, September 25, the UK’s Competition and Markets Authority (CMA) opened the public comment period for its antitrust investigation of the acquisition of Spark Therapeutics by Roche Holdings.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market.

    Full Content: Gov UK

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.